开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2024-08-21 ms5000000275258450 来自重庆

一修回去之后大概多久送审啊？

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2024-08-21 ms5000000275258450 来自重庆

请问一修回去后大概多久送审？

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2024-05-01 ms2000001028543384 来自陕西省

还没有

41 0

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2023-10-19 PILIXIA 来自上海

请问一审周期是多久呢

65 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2023-11-25 ms2000000406721606

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：细胞生物学
经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开

74 0

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2022-10-22 slientwo

偏重的研究方向：分子生物学;细胞生物学
经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。

109 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2023-05-25 148a4d45m01暂无昵称来自上海

编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~

81 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2018-07-20 毛大丁

已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？

487 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2022-04-20 tomsyu

这个杂志送审后会是什么状态？会有出现review zip吗

114 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221762, encodeId=4c152221e6234, content=一修回去之后大概多久送审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:20:49 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2221765, encodeId=8b252221e65a7, content=请问一修回去后大概多久送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeab8656599, createdName=ms5000000275258450, createdTime=Wed Aug 21 19:23:22 CST 2024, time=2024-08-21, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163684, encodeId=849a2163684c6, content=请问一审周期是多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Thu Oct 19 09:55:21 CST 2023, time=2023-10-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095400, encodeId=56d42095400a2, content=偏重的研究方向：分子生物学;细胞生物学 经验分享：EMBO J的编辑部极其严谨，负责各个研究方向的Senior Scientific Editor有着扎实的研究背景，处理稿件态度友好，发出去邮件几乎都是第二天就有回复。EMBO出版社的办刊理念有超前的发展思路，公开同行评审起先于EMBO出版社，这给很多杂志做了样板，在业内具有广泛的影响。EMBO旗下不光EMBO J，EMBO reports在生物学领域也是可圈可点，在系统生物学领域创立了Molecular systems biology，在分子药物研发领域创立了EMBO molecular medicine。前几年，由EMBO出版社牵头，联合另外两大行业巨头冷泉港实验室和洛克菲勒大学共同创立了Life Science Alliance杂志，风格以EMBO出版社为主。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Oct 22 17:17:04 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2139044, encodeId=6b4c2139044e4, content=编辑手里9天了还没有送审，是不是编辑手里时间长的容易不送审啊~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14765319187, createdName=148a4d45m01暂无昵称, createdTime=Thu May 25 21:10:56 CST 2023, time=2023-05-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=559413, encodeId=867c559413a3, content=已经under consideration20天了，不知道有没有送审，之前投这个杂志的兄弟有过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=487, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Jul 20 14:20:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212909, encodeId=7bc6121290905, content=这个杂志送审后会是什么状态？会有出现review zip吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 20 18:22:43 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202565, encodeId=26541202565c3, content=这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=388b5502801, createdName=ms4000000641054978, createdTime=Mon Mar 14 20:26:27 CST 2022, time=2022-03-14, status=1, ipAttribution=)]

2022-03-14 ms4000000641054978

这个杂志从投稿到一审结束，会不会从Under Editorial Consideration 变到Under review？

111 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务